H.B. Fuller (NYSE:FUL) announced that its board rejected Ancora’s unsolicited, non-binding proposal to acquire its Building Adhesives Solutions business, stating that the offer undervalues the segment.
Spruce Biosciences (NASDAQ:SPRB) announced that it completed two pre-BLA meetings with the U.S. Food and Drug Administration supporting its planned submission of a Biologics License Application for tralesinidase alfa enzyme replacement therapy in Sanfilippo Syndrome Type B.
The9 (NASDAQ:NCTY) reported unaudited net income of US$32 million for the quarter ended June 30, 2026, up more than 39% from the previous quarter, driven mainly by fair-value recognition of 9BIT tokens.
Insmed (NASDAQ:INSM) announced that Japan’s Ministry of Health, Labour and Welfare approved BRINSUPRI (brensocatib 25 mg) for adults and pediatric patients aged 12 years and older with non-cystic fibrosis bronchiectasis.
BriaCell (NASDAQ:BCTX) announced that Bria-MEL+ has passed a key genetic engineering milestone, moving the personalized whole-cell melanoma immunotherapy vaccine candidate toward potential clinical development.
Vanda Pharmaceuticals (NASDAQ:VNDA) announced that the European Commission granted orphan designation to imsidolimab for the treatment of generalized pustular psoriasis, following a positive opinion from the EMA Committee for Orphan Medicinal Products.
NAPCO Security Technologies (NASDAQ:NSSC) reported fiscal Q4 2026 revenue of $55.8 million, up 10% year-over-year, driven by growth in recurring service and equipment revenue.
Scinai Immunotherapeutics (NASDAQ:SCNI) reported first-half 2026 revenue of $949 thousand, up from $773 thousand a year earlier, driven mainly by its acquired Yavne contract development and manufacturing organization operations.
Martin Marietta (NYSE:MLM) completed its previously announced combination with Lhoist North America, a subsidiary of Lhoist Group, effective August 21, 2026.
Gogoro (NASDAQ:GGR) reported Q2 2026 revenue of $70.6 million, up 7.3% year-over-year, supported by higher hardware and other revenue.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
